國立虎尾科技大學 |

Resistance to molecular therapies for hepatocellular carcinoma

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Resistance to molecular therapies for hepatocellular carcinoma/ edited by Augusto Villanueva.
other author:	Villanueva, Augusto.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xiii, 147 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Liver - Cancer -
Online resource:	http://dx.doi.org/10.1007/978-3-319-56197-4
ISBN:	9783319561974

Resistance to molecular therapies for hepatocellular carcinoma
Resistance to molecular therapies for hepatocellular carcinoma[electronic resource] /edited by Augusto Villanueva. - Cham :Springer International Publishing :2017. - xiii, 147 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.132196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma -- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma -- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance -- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance -- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma -- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma -- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma -- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

ISBN: 9783319561974

Standard No.: 10.1007/978-3-319-56197-4doiSubjects--Topical Terms:

1198591
Liver
--Cancer

LC Class. No.: RC280.L5

Dewey Class. No.: 616.99436061

Resistance to molecular therapies for hepatocellular carcinoma
LDR:02354nam a2200325 a 4500 001 922765
003 DE-He213
005 20170717181551.0
006 m d
007 cr nn 008maaau
008 190625s2017 gw s 0 eng d
020 $a 9783319561974 $q (electronic bk.)
020 $a 9783319561967 $q (paper)
024 7 $a 10.1007/978-3-319-56197-4 $2 doi
035 $a 978-3-319-56197-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99436061 $2 23
090 $a RC280.L5 $b R433 2017
245 0 0 $a Resistance to molecular therapies for hepatocellular carcinoma $h [electronic resource] / $c edited by Augusto Villanueva.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiii, 147 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.13
505 0 $a Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma -- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma -- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance -- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance -- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma -- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma -- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma -- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
520 $a This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
650 0 $a Liver $x Cancer $x Chemotherapy. $3 1198591
650 0 $a Drug resistance in cancer cells. $3 681914
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
700 1 $a Villanueva, Augusto. $3 1198590
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 1063064
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-56197-4
950 $a Biomedical and Life Sciences (Springer-11642)